Jaivir Pall

Traditional insulin replacement therapy involves multiple daily insulin injections or the delivery of insulin by a pump, the need for careful blood glucose monitoring, and the fear of an unwanted fall in blood glucose (hypoglycemia). Fear of hypoglycemia prevents optimal glycemic management leading to long-term hyperglycemia and damage to the body (kidney, heart, extremities). Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management. ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.

IDF Europe is the European chapter of the International Diabetes Federation (IDF). We are a diverse and inclusive multicultural network of 72 national diabetes associations in 45 countries, representing both people living with diabetes and healthcare professionals. Our vision is to improve the lives of people with diabetes and our mission, in Europe, is to unite the voice of people with diabetes and to engage all stakeholders in creating a person-centred diabetes ecosystem.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

Biosapien is a late-stage pre clinical company focused on novel drug delivery platforms.

Traditional insulin replacement therapy involves multiple daily insulin injections or the delivery of insulin by a pump, the need for careful blood glucose monitoring, and the fear of an unwanted fall in blood glucose (hypoglycemia). Fear of hypoglycemia prevents optimal glycemic management leading to long-term hyperglycemia and damage to the body (kidney, heart, extremities). Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management. ABV100: A titratable, fixed ratio combination of two FDA-approved peptides to control glycemia while mitigating the threat of hypoglycemia.

IDF Europe is the European chapter of the International Diabetes Federation (IDF). We are a diverse and inclusive multicultural network of 72 national diabetes associations in 45 countries, representing both people living with diabetes and healthcare professionals. Our vision is to improve the lives of people with diabetes and our mission, in Europe, is to unite the voice of people with diabetes and to engage all stakeholders in creating a person-centred diabetes ecosystem.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

We create innovative impact investment and advisory solutions that incorporate current and future environmental and social opportunities and risks, as we believe these will benefit from a competitive advantage and improved long-term financial prospects.

Biosapien is a late-stage pre clinical company focused on novel drug delivery platforms.